Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label, Randomized, Comparative Phase 2 Study of Combination Immunotherapy Plus Standard-of-care Chemotherapy Versus Standard-of-care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer

NCT04390399 is registered in ClinicalTrials.gov with ImmunityBio, Inc. as lead sponsor.

NCT NCT04390399
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04390399 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label, Randomized, Comparative Phase 2 Study of Combination Immunotherapy Plus Standard-of-care Chemotherapy Versus Standard-of-care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer
Lead sponsor
ImmunityBio, Inc.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
July 21, 2020
Completion date
May 31, 2026
Enrollment
328 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer